Why fund managers are divided on Healius's pathology turnaround
Healius keeps cutting costs and growing core pathology revenue ahead of the industry, but weak GP volumes and funding pressure have made its turnaround extremely volatile.
31 May 2026 · 6 min read
In short
Healius reduced headcount by 400 full-time equivalents while growing core pathology revenue 3.5% year on year, outperforming flat industry-wide Medicare volume trends.
The stock fell 32.7% in May 2026 after worse-than-expected GP pathology volumes drove a 4.1% EBITDA downgrade, with no government indexation funding relief.
Competitor 4Cyte Pathology grew revenue 33% in FY25, an aggressive expansion that Spheria Asset Management says is impacting rival ACL more severely than Healius.
Pathology and diagnostics provider Healius has struggled to convince the market its cost-cutting and mix-shift turnaround is working, with Ellerston Capital's May 2026 Monthly Report detailing a further 32.7% detraction from its overweight position after worse-than-expected GP pathology volumes in April drove a 4.1% EBITDA downgrade, with no indexation funding relief forthcoming from the Federal Government.
Real cost cuts, but revenue remains the swing factor
Spheria Asset Management's February 2026 Monthly Report argued the market's reaction to the company's first-half FY26 result, a 24% share price fall, was disproportionately negative given what was actually delivered: core pathology revenue grew 3.5% year on year, outperforming flat industry-wide Medicare volume trends, while headcount was reduced by 400 full-time equivalents, or 2.2%, with further benefits expected to flow through in the second half. Blackwattle Investment Partners' own February 2026 report was more skeptical, noting cost savings were largely complete and would only annualise into the second half, leaving the expected earnings uplift dependent on pathology volumes that provide little certainty, with the balance sheet at risk of returning to a net debt position.
Overall, while the result highlighted solid operational progress in revenue mix, cost control, and outperformance vs. industry volumes, the share price reaction seemed disproportionately negative given what was expected.
— Spheria Asset Management, Monthly Report, February 2026
Spheria's report also flagged an industry dynamic working against Healius: competitor 4Cyte Pathology grew revenue 33% in FY25 to $274 million with a 5% EBIT margin, an aggressive expansion that appears to be impacting rival ACL more severely than Healius, even as new B12 and urine test funding changes created additional headwinds during the half. Wentworth Williamson's December 2025 Quarterly Report had initiated a modest position reflecting conviction in the medium-term turnaround and value-realisation potential, while Ellerston Capital had named Healius among a group of key holdings, alongside Domino's, Aurizon and Washington H. Soul Pattinson, that it viewed as out of favour and completely mispriced with strong earnings turnaround potential.
What managers are watching next
The stock's volatility has been extreme through the turnaround: Ellerston Capital's reports show swings from a 10.1% positive contribution in November 2025 to a 7.7% detraction in December, followed by the sharp 32.7% May 2026 fall. With net cash having already declined to just $12 million as at 31 December 2025 due to a legacy tax payment and a working capital true-up related to the Lumus sale, managers are watching whether the annualising cost savings can finally offset ongoing GP pathology volume softness before the balance sheet slips further into net debt.
Questions
Why is Healius's turnaround considered risky by fund managers?
Blackwattle Investment Partners notes Healius's cost savings are largely complete and will only annualise into the second half, leaving the expected earnings uplift heavily dependent on pathology volumes that provide little certainty, with the balance sheet at risk of returning to a net debt position.
How is Healius performing against the pathology industry?
According to Spheria Asset Management, Healius grew core pathology revenue 3.5% year on year in its first half FY26 result, outperforming flat industry-wide Medicare volume trends, even as new B12 and urine test funding changes created additional headwinds.
Why did Healius's share price fall sharply in May 2026?
Healius fell 32.7% in May 2026 after worse-than-expected GP pathology volumes in April drove a 4.1% EBITDA downgrade, with no indexation funding relief provided by the Federal Government.
9 managers, 21 comments, with each manager's latest recorded position.
See HLS